Results 281 to 290 of about 4,521,628 (366)

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Expanding diagnostic testing for drug-resistant tuberculosis in high burden settings: a cost-effectiveness analysis. [PDF]

BMC Public Health
Getchell M, Ansah JP, Lim D, Basilio R, Tablizo F, Corpuz C, Matchar D.   +6 more
europepmc   +1 more source

AUTOMATION OF FUNCTIONAL-COST ANALYSIS AND THE METHOD OF "DIRECTCOSTING" ON THE BASIS OF ASC-ANALYSIS AND "EIDOS" SYSTEM (AUTOMATED CONTROL OF PHYSICAL AND FINANCIAL COST EFFECTIVENESS WITHOUT SUBSTANTIAL TECHNOLOGICAL AND FINANCIAL-ECONOMIC CALCULATIONS BASED ON INFORMATION AND COGNITIVE TECHNOLOGIES AND THE CONTROL THEORY)

, 2017
Y. V. Lutsenko
openalex   +1 more source

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

Arthritis Care &Research, Accepted Article.
Objectives Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies. To help patients and providers in the decision‐making process, we developed
Anahita Deboo, Robert Fox, Katherine M. Hammitt, Julie Frantsve‐Hawley, Matthew C. Baker, Stamatina Danielides, Eduardo De Sousa, Brent P. Goodman, Jennifer K. King, Steven Mandel, Ghaith Noaiseh, Pantelis P. Pavlakis, George Sarka, R. Hal Scofield, Arun Varadhachary, Daniel J. Wallace, Matt Makara, Nancy Carteron, Steven Carsons, In collaboration with the Consensus Expert Panel (CEP) members   +19 more
wiley   +1 more source

PRICE: a personalized recursive intelligent cost effectiveness analysis framework for rare disease diagnosis. [PDF]

BMC Med Inform Decis Mak
Nie M, Yao Y, Kim J, Liu C.
europepmc   +1 more source

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis‐Associated Interstitial Lung Disease Risk

Arthritis Care &Research, Accepted Article.
Objective The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase (MMP)‐7, and serum anti‐malondialdehyde‐acetaldehyde (anti‐MAA) antibody for RA‐associated interstitial lung disease risk stratification. Methods Using a multicenter cohort of US veterans with RA, we performed a cross‐
Kelsey Coziahr, Austin M. Wheeler, Brent A. Luedders, Michael Duryee, Halie Frideres, Katherine D. Wysham, Grant W. Cannon, Gary Kunkel, Dana P. Ascherman, Paul A. Monach, Gail S. Kerr, Andreas M. Reimold, Scott M. Matson, Joshua F. Baker, Geoffrey M. Thiele, Ted R. Mikuls, Bryant R. England   +16 more
wiley   +1 more source

Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan. [PDF]

Cancer Med
Sasahara Y, Takumoto Y, Murata T, Akazawa M, Narimatsu H.   +4 more
europepmc   +1 more source

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

Arthritis Care &Research, Accepted Article.
Background Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined: 1) associations between economic insecurities and PROs; 2) the impact of screening and addressing economic insecurities during ...
Jay Patel, Tripti Singh, Meredith Ingersoll, Shelby Gomez, Amanda Weber, Sarah E. Panzer, Sancia Ferguson, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Development of a cost-effectiveness analysis model for Duchenne muscular dystrophy utilizing the national registry in Japan. [PDF]

Sci Rep
Okada T, Komaki H, Ishizuka T, Oba M, Hori S, Nakamura H.   +5 more
europepmc   +1 more source

PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS: RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS

, 2005
Pendar Farahani, Ron Goeree, Kathryn Gaebel, Mitchell Levine   +3 more
openalex   +1 more source